{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:37:31Z","timestamp":1787063851635,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A German expert committee recommends defining fast-track clinics (FTC) for the acute diagnosis of giant cell arteritis (GCA) as follows: easy and prompt reachability at least on weekdays, scheduling appointments ideally within 24\u202fh, examination by a\u00a0specialist with GCA expertise, \u2265\u202f2\u00a0experts per FTC, \u2265\u202f50\u00a0patients with suspected GCA per year, sonologists with \u2265\u202f300 (\u2265\u202f50) temporal and axillary artery examinations, adherence to standard operating procedures, availability of an \u2265\u202f18 (\u2265\u202f15)\u202fMHz and a\u00a0lower frequency linear ultrasound probe, and collaboration with partners for neurology and ophthalmology consultations, magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT, possibly CT), and for temporal artery biopsy.<\/jats:p>","DOI":"10.1007\/s00393-024-01532-9","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:15:29Z","timestamp":1717488929000},"page":"285-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Recommendations for defining giant cell arteritis fast-track clinics. English version","Empfehlungen zur Definition von Riesenzellarteriitis-Fast-Track-Kliniken"],"prefix":"10.1007","volume":"83","author":[{"given":"Wolfgang A.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Czihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ohrndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin S.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"e003379","DOI":"10.1136\/rmdopen-2023-003379","volume":"9","author":"P Bosch","year":"2023","unstructured":"Bosch\u00a0P, Bond\u00a0M, Dejaco\u00a0C et\u00a0al (2023) Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a\u00a0systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. RMD Open 9:e3379","journal-title":"RMD Open"},{"key":"1532_CR2","doi-asserted-by":"publisher","unstructured":"Dejaco C, Ramiro S, Bond M et al (2024) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis 83;741-751. https:\/\/doi.org\/10.1136\/ard-2023-224543","DOI":"10.1136\/ard-2023-224543"},{"key":"1532_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos\u00a0AP, Haugeberg\u00a0G, Lindland\u00a0A et\u00a0al (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a\u00a0more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 55:66\u201370","journal-title":"Rheumatology"},{"key":"1532_CR4","doi-asserted-by":"publisher","unstructured":"Keller KK, Mukhtyar CB, Nielsen AW et\u00a0al (2023) Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group. Ann Rheum Dis Dec. https:\/\/doi.org\/10.1136\/ard-2023-225134","DOI":"10.1136\/ard-2023-225134"},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"589794","DOI":"10.3389\/fmed.2020.589794","volume":"7","author":"S Monti","year":"2020","unstructured":"Monti\u00a0S, Bartoletti\u00a0A, Bellis\u00a0E, Delvino\u00a0P et\u00a0al (2020) Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med 7:589794","journal-title":"Front Med"},{"issue":"2 Suppl 89","key":"1532_CR6","first-page":"S103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil\u00a0P, Williams\u00a0M, Maw\u00a0WW et\u00a0al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a\u00a0longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):S103\u2013S106","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"1532_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00393-021-01080-6","volume":"80","author":"A Pfeil","year":"2021","unstructured":"Pfeil\u00a0A, Krusche\u00a0M, Vossen\u00a0D et\u00a0al (2021) Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. Z\u00a0Rheumatol 80(Suppl 2):64\u201367 (English version)","journal-title":"Z Rheumatol"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3899\/jrheum.171428","volume":"45","author":"VS Sch\u00e4fer","year":"2018","unstructured":"Sch\u00e4fer\u00a0VS, Chrysidis\u00a0S, Dejaco\u00a0C et\u00a0al (2018) Assessing vasculitis in giant cell arteritis by ultrasound: Results of OMERACT patient-based reliability exercises. J\u00a0Rheumatol 45:1289\u20131295","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"1532_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, Balzer\u00a0K et\u00a0al (2020) S2k Guideline: Management of large vessel vasculitides. Z\u00a0Rheumatol 79(Suppl 3):67\u201395","journal-title":"Z Rheumatol"},{"issue":"Suppl 2","key":"1532_CR10","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt\u00a0WA (2018) Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology 57(Suppl 2):ii22\u2013ii31","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01532-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01532-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01532-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:02:58Z","timestamp":1734505378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01532-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":10,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01532-9","relation":{"is-translation-of":[{"id-type":"doi","id":"10.1007\/s00393-024-01519-6","asserted-by":"subject"},{"id-type":"doi","id":"10.1007\/s00393-024-01519-6","asserted-by":"object"}]},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"23 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The idea for drafting these recommendations originated in an expert panel initiated by Novartis Pharma GmbH, with 8\u00a0of 10\u00a0authors participating (all except VSS and WH). All subsequent activities for developing the recommendations were conducted independently of Novartis. W.A.\u00a0Schmidt: <i>Speaker <\/i>for Abbvie, Amgen, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Roche, UCB; <i>Consultant <\/i>for Abbvie, Amgen, Fresenius Kabi, GlaxoSmithKline, Novartis, Sanofi; <i>Research support <\/i>as principal investigator from Abbvie, GlaxoSmithKline, Novartis, Sanofi; <i>Member of recommendation initiatives <\/i>of EULAR (Imaging in rheumatoide arthritis, Management of PMR (EULAR\/ACR), conducting of ultrasound courses, ultrasound synovitis scoring, management of large vessel vasculitides, imaging in large vessel vasculitis 2018 and 2023, publication von research on ultrasound, imaging in crystal arthropathies); of the British Society for Rheumatology (diagnosis and management of GCA), of AWMF (management of large vessel vasculitis, management of gout) and the International GCA\/PMR Study Group (recommendations for early referral of individuals with suspected PMR). M.\u00a0Czihal: <i>Speaker <\/i>for Bayer, Bristol Myers Squibb, Lilly, Leo Pharma, MSD Sharp & Dohme, Novartis, Roche, UCB; <i>Consultant<\/i> for Novartis, Roche. M.\u00a0Gernert: <i>Speaker<\/i> for Abbvie, Lilly, Janssen, Novartis; <i>Consultant<\/i> for Amgen, Astrazeneca, Novartis, Takeda; <i>Congress sponsoring <\/i>from Abbvie, Lilly, Hexal, Janssen, Pfizer, UCB. W.\u00a0Hartung: <i>Speaker<\/i> for Abbvie, Amgen, Bristol Myers Squibb, Chugai, Novartis; Alpinion; Canon HealthCare; <i>Board Member <\/i>of DEGUM. B.\u00a0Hellmich: <i>Speaker <\/i>for Abbvie, AstraZeneca, BMS, GSK, Janssen, Novartis, Orgentec, Pfizer, Roche, Vifor; <i>Beraterhonorare <\/i>f\u00fcr Abbvie, BMS, InflaRx, GSK, Novartis, Roche, Vifor; <i>Member of recommendation initiatives: <\/i>The author was convenor of the EULAR Recommendations 2018 and the AWMF guidelines on management of large vessel vasculitis. S.\u00a0Ohrndorf: <i>Speaker <\/i>for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb (BMS), Galapagos (Alfasigma), Janssen, Mylan, Novartis, UCB; <i>Consultant <\/i>for Amgen, Janssen, Novartis; <i>Research support<\/i> as Principal Investigator for Novartis. G.\u00a0Riemekasten: <i>Consultant <\/i>for Novartis. V.\u00a0Sch\u00e4fer: <i>Speaker <\/i>for AbbVie, Novartis, BMS, Chugai, Celgene, Medac, Sanofi, Lilly, Hexal, Pfizer, Janssen, Roche, Schire, Onkowissen, Royal College London, Boehringer-Ingelheim, UCB Fresenius, Alexion; <i>Consultant <\/i>for Novartis, Chugai, AbbVie, Celgene, Sanofi, Lilly, Hexal, Pfizer, Amgen, BMS, Roche, Gilead, Medac, Boehringer-Ingelheim, Alexion; <i>Research support <\/i>from Novartis, Hexal, Lilly, Roche, Celgene, Universit\u00e4t Bonn, Boehringer-Ingelheim, Butterfly IQ, MEDAC, Alexion, DGRh. J.\u00a0Strunk: <i>Speaker and Consultant<\/i> for AbbVie, Amgen, Chugai, BMS, Boehringer, GSK, Galapagos, Janssen-Cilag, Medac, Novartis, Pfizer, Roche, Sanofi, UCB. N.\u00a0Venhoff: <i>Speaker<\/i> for AbbVie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Celgene, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Consultant<\/i> for AbbVie, AstraZeneca, Boehringer-Ingelheim, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Research support<\/i> from AbbVie, Medac, Novartis, Pfizer. <i>Member of recommendation initiative <\/i>of AWMF for management of large vessel vasculitis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}